Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction

Next Previous
Trial Profile

A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SERCA 2a gene therapy (Primary)
  • Indications Cardiomyopathies; Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MUSIC-HFrEF1
  • Sponsors Sardocor

Most Recent Events

  • 22 Oct 2025 According to a Medera media release, The initiation of Phase 2 follows the independent Data and Safety Monitoring Board's (DSMB) recommendation in March 2025 to advance the trial based on its review of data from all nine patients in the Phase 1b portion.
  • 22 Oct 2025 According to a Medera media release, first patient has been dosed in the Phase 2 portion of this trial. The patient was successfully treated on September 5, 2025, and additional patients are scheduled for treatment.
  • 13 Jun 2025 According to a Medera media release, data from this trial was presented at the 2025 International Society for Stem Cell Research (ISSCR) Annual Meeting, held June 11 to 14 in Hong Kong.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top